Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...
Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.
Most second cancers detected within 6 yrs Irfan Tramboo Srinagar, May 15: A five-year study conducted by researchers at ...
Health eCareers on MSN
Find your niche: Exploring career paths in ob-gyn subspecialties
Ob-Gyn residents today have more career paths available than ever before. Fellowship training opportunities exist in a ...
The intensive care unit at the Vladimir Ilich Lenin University Teaching Hospital in Holguin province. It continues to operate ...
For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results